Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin
Copyright © 2018 Elsevier Ltd. All rights reserved..
Recent studies demonstrated that inhibitors of pro-inflammatory molecular cascades triggered by rabies infection in the central nervous system (CNS) can enhance survival in mouse model and that certain antiviral compounds interfere with rabies virus replication in vitro. In this study different combinations of therapeutics were tested to evaluate their effect on survival in rabies-infected mice, as well as on viral load in the CNS. C57Bl/6 mice were infected with Silver-haired bat rabies virus (SHBRV)-18 at virus dose approaching LD50 and LD100. In one experimental group daily treatments were initiated 4 h before-, in other groups 48 or 96 h after challenge. In the first experiment therapeutic combination contained inhibitors of tumour necrosis factor-α (infliximab), caspase-1 (Ac-YVAD-cmk), and a multikinase inhibitor (sorafenib). In the treated groups there was a notable but not significant increase of survival compared to the virus infected, non-treated mice. The addition of human rabies immunoglobulins (HRIG) to the combination in the second experiment almost completely prevented mortality in the pre-exposure treatment group along with a significant reduction of viral titres in the CNS. Post-exposure treatments also greatly improved survival rates. As part of the combination with immunomodulatory compounds, HRIG had a higher impact on survival than alone. In the third experiment the combination was further supplemented with type-I interferons, ribavirin and favipiravir (T-705). As a blood-brain barrier opener, mannitol was also administered. This treatment was unable to prevent lethal consequences of SHBRV-18 infection; furthermore, it caused toxicity in treated mice, presumably due to interaction among the components. In all experiments, viral loads in the CNS were similar in mice that succumbed to rabies regardless of treatment. According to the findings, inhibitors of detrimental host response to rabies combined with antibodies can be considered among the possible therapeutic and post-exposure options in human rabies cases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Vaccine - 37(2019), 33 vom: 02. Aug., Seite 4724-4735 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marosi, András [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 27.07.2020 Date Revised 27.07.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2018.05.066 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM284506370 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM284506370 | ||
| 003 | DE-627 | ||
| 005 | 20231225043356.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2018.05.066 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0948.xml |
| 035 | |a (DE-627)NLM284506370 | ||
| 035 | |a (NLM)29805091 | ||
| 035 | |a (PII)S0264-410X(18)30706-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marosi, András |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.07.2020 | ||
| 500 | |a Date Revised 27.07.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Recent studies demonstrated that inhibitors of pro-inflammatory molecular cascades triggered by rabies infection in the central nervous system (CNS) can enhance survival in mouse model and that certain antiviral compounds interfere with rabies virus replication in vitro. In this study different combinations of therapeutics were tested to evaluate their effect on survival in rabies-infected mice, as well as on viral load in the CNS. C57Bl/6 mice were infected with Silver-haired bat rabies virus (SHBRV)-18 at virus dose approaching LD50 and LD100. In one experimental group daily treatments were initiated 4 h before-, in other groups 48 or 96 h after challenge. In the first experiment therapeutic combination contained inhibitors of tumour necrosis factor-α (infliximab), caspase-1 (Ac-YVAD-cmk), and a multikinase inhibitor (sorafenib). In the treated groups there was a notable but not significant increase of survival compared to the virus infected, non-treated mice. The addition of human rabies immunoglobulins (HRIG) to the combination in the second experiment almost completely prevented mortality in the pre-exposure treatment group along with a significant reduction of viral titres in the CNS. Post-exposure treatments also greatly improved survival rates. As part of the combination with immunomodulatory compounds, HRIG had a higher impact on survival than alone. In the third experiment the combination was further supplemented with type-I interferons, ribavirin and favipiravir (T-705). As a blood-brain barrier opener, mannitol was also administered. This treatment was unable to prevent lethal consequences of SHBRV-18 infection; furthermore, it caused toxicity in treated mice, presumably due to interaction among the components. In all experiments, viral loads in the CNS were similar in mice that succumbed to rabies regardless of treatment. According to the findings, inhibitors of detrimental host response to rabies combined with antibodies can be considered among the possible therapeutic and post-exposure options in human rabies cases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Combination | |
| 650 | 4 | |a HRIG | |
| 650 | 4 | |a Infliximab | |
| 650 | 4 | |a Rabies virus | |
| 650 | 4 | |a Sorafenib | |
| 650 | 4 | |a Survival | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Immunoglobulins |2 NLM | |
| 700 | 1 | |a Dufkova, Lucie |e verfasserin |4 aut | |
| 700 | 1 | |a Forró, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Felde, Orsolya |e verfasserin |4 aut | |
| 700 | 1 | |a Erdélyi, Károly |e verfasserin |4 aut | |
| 700 | 1 | |a Širmarová, Jana |e verfasserin |4 aut | |
| 700 | 1 | |a Palus, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Hönig, Václav |e verfasserin |4 aut | |
| 700 | 1 | |a Salát, Jiří |e verfasserin |4 aut | |
| 700 | 1 | |a Tikos, Réka |e verfasserin |4 aut | |
| 700 | 1 | |a Gyuranecz, Miklós |e verfasserin |4 aut | |
| 700 | 1 | |a Růžek, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Martina, Byron |e verfasserin |4 aut | |
| 700 | 1 | |a Koraka, Penelope |e verfasserin |4 aut | |
| 700 | 1 | |a Osterhaus, Albert D M E |e verfasserin |4 aut | |
| 700 | 1 | |a Bakonyi, Tamás |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 37(2019), 33 vom: 02. Aug., Seite 4724-4735 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2019 |g number:33 |g day:02 |g month:08 |g pages:4724-4735 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2018.05.066 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2019 |e 33 |b 02 |c 08 |h 4724-4735 | ||